This opportunity funds research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those used for tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. It emphasizes rapid genotypic and improved phenotypic methods that bypass slow culture-based processes, aiming to reduce drug resistance and improve patient outcomes by enabling timely and effective treatment.
Eligible applicants include a wide range of entities such as state, county, city, and tribal governments, public and private educational institutions, nonprofits, for-profit organizations including small businesses, federal agencies, U.S. territories, faith-based and community organizations, and for
